1Cell.Ai
OncoMonitor®
Longitudinal Monitoring Test

A Novel Liquid Biopsy Test for Longitudinal Cancer Monitoring

OncoMonitor®MRD is a blood test designed for Longitudinal Cancer Monitoring and Minimal Residual Disease Detection, by measuring CTC & ctDNA.



OncoMonitor® TRM is a liquid biopsy-based solution designed for monitoring treatment response, emergence of resistance and tracking disease progression.

OncoMonitor®MRD Benefits

Minimal Residual Disease Detection

OncoMonitor's ability to identify trace amounts of ctDNA and CTCs allows for early detection of residual cancer cells post-treatment, enabling timely intervention and improved patient outcomes.

Prognostic Value

CTC and ctDNA levels have shown prognostic significance in various cancers. The test results can help predict disease progression and overall survival, aiding in informed decision- making for both patients and healthcare providers.

ctDNA epigenomics validation results

Sensitivity	90.5%
PPV	95%
Specificity	97.2%
NPV	94.6%
Concordance	94.7%
Limit of Detection (LOD)	0.05

Analysis done on 57 samples which includes Seraseq® reference standards and healthy individual samples

OncoMonitor® TRM Benefits

Longitudinal Monitoring

By regularly assessing CTC numbers and ctDNA load, oncologists can gain insights into the dynamics of the disease, its response to treatment, and potential disease relapse.

Treatment Efficacy Assessment

Changes in CTC counts and ctDNA levels can indicate whether the current treatment approach is successful or if modifications are necessary to enhance its impact.

For which cancer phase is OncoMonitor® most applicable?

Applicability Across Cancer Journey: Tracking Disease Progression and Relapse Detection Through Longitudinal Blood-Based Monitoring



Comparison of OncoMonitor® MRD and OncoMonitor® TRM

	OncoMonitor® MRD	OncoMonitor® TRM
Eligibility	Early-stage post-curative intent surgery	Advanced metastatic cancers
Features	Cellulomics and Epigenomics	Cellulomics, Epigenomics, and Genomics (mutation profiling)
Clinical Decisions	1. Escalation or de-escalation in adjuvant setting 2. Surveillance of tumor burden 3. MRD assessment	1. Early course correction 2. Predicting therapy response 3. Disease progression prediction
Test Type	Prognostic/Predictive test	Predictive test
Indications	Colon, Rectal, Breast, Bladder, Prostate, and Ovary cancers	All Solid Tumors



Test Performance Characteristics:

- **Genomic Alterations Coverage:** Detects SNVs, INDELs, CNVs, and selected fusions (by DNA) in targeted genes (exclusive to TRM).
- **AI-Powered Reporting:** Enabled via iCARE™.
- **Sequencing Depth:** 10,000x mean depth.
- **Gene Coverage:** 99% mean coverage across all included genes.
- **Fusion Gene Analysis:** Covers 30 fusion genes with 40 corresponding partner genes, including DNA-based fusions.
- **Variant Calling Databases:** Utilizes approximately 20 databases.
- **MSI Status:** Assessed by NGS.
- **PD-L1 Expression Analysis:** Evaluated via immunofluorescence on OncoDiscover-CTC.
- **Indications:** Solid tumors.
- **CTC Detection:** Enabled through DCGI-approved OncoDiscover® technology.
- **DNA Methylation Profiling:** Covers over 3,440 CpG sites.
- **Sample Type & Volume:** Peripheral blood | 3 tubes (10ml PAXgene in 2 tubes, 10ml K2 EDTA in 1 tube).

Key Actionable Genes Include in OncoMonitor TRM:

Lung
AKT1, ALK, BRAF, ERBB2 (Her2), EGFR, FGFR 1/2/3, HRAS, KRAS, MAP2K1, MET, NRAS, NTRK 1/2/3, PIK3CA, PTEN, RET, ROS1, TP53

Breast
AKT1, AR, BRCA1, BRCA2, ERBB2 (Her2), ESR1, FGFR 1/2/3, NTRK 1/2/3, PALB2, PIK3CA, PTEN, TP53

Melanoma
BRAF, CTNNB1, GNA1, GNAQ, HRAS, KIT, KRAS, MAP2K1, NF1, NRAS, NTRK 1/2/3, PDGFRA, PIK3CA, PTEN, TP53

Bladder
MLH1, MSH2, MSH6, NTRK 1/2/3, PMS2, TP53, TSC1

Colorectal
AKT1, BRAF, HRAS, KRAS, MET, MLH1, MSH2, MSH6, NRAS, NTRK 1/2/3, PIK3CA, PMS2, PTEN, SMAD4, TP53

Ovary
BRAF, BRCA1, BRCA2, HRAS, KRAS, NRAS, NTRK 1/2/3, PALB2, PDGFRA, TP53

Gastrointestinal
BRAF, KIT, KRAS, MET, MLH1, MSH2, MSH6, NTRK 1/2/3, PDGFRA, PMS2, SMAD4, TP53

Pioneering Precision Monitoring

Navigating Cancer's Ebb and Flow

Longitudinal Monitoring

Assess disease dynamics over time

Minimal Residual Disease detection

Uncover residual cancer cells post-treatment

AI powered Real-time results

Swift and accurate AI powered comprehensive reporting

1Cell.Ai™
Ai-Powered Precision Oncology

CAP ACCREDITED
COLLEGE of AMERICAN PATHOLOGISTS

MC-7348

Learn More at 1Cell.Ai

Mail - info@1cell.ai | Tel - 1800 123 12355

1CAi-03-03-042025